CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 27 enrolled
Drug / intervention
imiquimod 5% creamdrug
Likely dose
imiquimod 5% cream 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00774787
NCT00774787Phase 4Completed
CompareCT.gov

A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses

Rigel Dermatology·interventional·Posted Oct 17, 2008·Updated Nov 7, 2016

In Brief

A Phase 4 clinical trial evaluating imiquimod 5% cream for Actinic Keratoses. Completed, enrolled 27 participants across 3 sites.

Detailed Summary

The purpose of this study is to determine if use of topical imiquimod cream after cryotherapy of actinic keratoses reduces the total number of lesions (those treated with cryotherapy and new ones) at follow-up.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratoses
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 17, 2008
Enrollment StartOct 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.7 years ago

Interventions

imiquimod 5% creamdrug

1 packet (250 mg cream) 3 times per week for 4 weeks